Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk c19hcq.org Shoaibi et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 29,451 patients in the USA Lower mortality with HCQ (p=0.001) Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463 Favors HCQ Favors control
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463 (Preprint)
Shoaibi et al., Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients, medRxiv, doi:10.1101/2020.09.23.20199463 (Preprint)
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%). This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199463; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Title: Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients short title: Famotidine and risk of COVID-19 outcomes Authors: Azza Shoaibi PhD, Stephen Fortin PharmD MS, Rachel Weinstein PhD, Jesse A. Berlin ScD, Patrick Ryan PhD Author Azza Shoaibi Email ashoaibi@its.jnj.com Position, department Associate director, observational health data analytics Stephen Fortin SFortin1@ITS.JNJ.com Manager, observational health data analytics Janssen Research & Development, LLC, Titusville, NJ, USA Rachel Weinstein RWeinst1@its.jnj.com Senior director, consumer epidemiology Janssen Research & Development, LLC, Titusville, NJ, USA Jesse Berlin JBerlin@its.jnj.com Johnson & Johnson Patrick Ryan PRyan4@its.jnj.com VP observational health data analytics VP, J&J epidemiology Affiliation Janssen Research & Development, LLC, Titusville, NJ, USA Janssen Research & Development, LLC, Titusville, NJ, USA Disclosures: AS, SF, RW, PBR are employees of Janssen Research and Development and shareholder of Johnson & Johnson, the product manufacturer of famotidine. JB is an employee and shareholder of Johnson & Johnson. Abbreviations Common Data Model Confidence interval Gastroesophageal reflux disease hazard ratios minimum detectible risk ratio Observational Health and Data Sciences and Informatics Observational Medical Outcomes Partnership Premier Hospital Database (PHD propensity score proton pump inhibitors standardized mean differences CDM CI GERD HRs MDRR OHDSI OMOP PHD PS PPI SMD Correspondence: Azza Shoaibi, MPH, PhD, 1125 Trenton-Harbourton Road, Titusville NJ, USA, 609 7302787, ashoaibi@its.jnj.com Tel: +1 Author Contributions: All authors contributed to the conceptualization and design of the study. SF authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors reviewed and contributed to the manuscript writing. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199463; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Abstract (260 words): Background: Famotidine has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine nonusers separately. Methods: We constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic health records. Study population were COVID-19 hospitalized patients aged 18 years or older. Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any medication containing one of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit